CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
MWN-AI** Summary
MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company based in Carmel, Indiana, has announced a successful End-of-Phase 2 (EOP2) meeting with the U.S. FDA regarding its once-weekly treatment, canvuparatide, for chronic hypoparathyroidism (HP). Dr. Sam Azoulay, MBX's Chief Medical Officer, expressed optimism about the feedback received during the meeting, emphasizing the drug's potential to establish a new standard of care by restoring normal parathyroid hormone (PTH) activity and achieving normocalcemia, all while offering the convenience of a once-weekly dosing regimen.
Following the FDA’s guidance, MBX plans to advance canvuparatide into Phase 3 trials set to begin in Q3 2026. The planned study will involve approximately 160 patients, randomly assigned in a 3:1 ratio to receive either canvuparatide or a placebo. Patients in the trial will first undergo a 4-week fixed dose period of 600 micrograms of canvuparatide, followed by an 18-week dose titration phase and concluding with a 4-week maintenance period. Efficacy will be primarily evaluated at the 26-week mark, leading into an open-label extension study for long-term safety and effect durability.
In addition to this advancement, canvuparatide has also received orphan drug designation from the European Medicines Agency, aiding its continued development in the European market. Hypoparathyroidism affects an estimated 250,000 people in the U.S. and Europe, and current treatments primarily focus on managing symptoms without addressing the underlying hormonal deficiency. MBX's emphasis on canvuparatide aligns with its mission of creating innovative peptide therapies for endocrine disorders.
MWN-AI** Analysis
MBX Biosciences, Inc. (Nasdaq: MBX) has recently made notable strides in its Phase 3 development of canvuparatide, aimed at treating chronic hypoparathyroidism (HP). The successful completion of its End-of-Phase 2 meeting with the FDA signifies regulatory support, paving the way for a Phase 3 trial slated to begin in Q3 2026. Investors should monitor this development closely, as it reflects the company's commitment to addressing unmet medical needs within this rare endocrine disorder.
The transition to a once-weekly dosing regimen is particularly promising. It could enhance patient compliance and overall treatment experience, potentially leading to higher enrollment figures in the Phase 3 trial. The trial's structured design, which incorporates a 4-week fixed dose and a subsequent titration period, is strategically focused on achieving clinically meaningful endpoints. The positive endpoint results, particularly concerning normal serum calcium levels, will be crucial for validating canvuparatide’s efficacy in the treatment landscape.
However, it's essential to remember the inherent risks involved in clinical development. Potential delays or failures in trials, along with regulatory hurdles, can negatively impact the stock’s performance. Investors should remain aware that while the orphan drug designation by the European Medicines Agency represents an opportunity for market expansion, it also places considerable pressure on MBX to deliver results.
In conclusion, while MBX Biosciences presents an attractive investment case given its innovative approach and promising pipeline, a cautious outlook should prevail. Keeping an eye on trial milestones and broader market trends will be essential for making informed investment decisions in this dynamic sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
In the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows.
CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) to discuss the overall Phase 3 trial design for once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP).
“We are very encouraged by the outcome of our End-of-Phase 2 meeting and the constructive feedback supporting our planned Phase 3 trial for canvuparatide,” said Sam Azoulay, M.D., Chief Medical Officer of MBX Biosciences. “We believe canvuparatide has the potential to establish a new standard of care in hypoparathyroidism by restoring physiologic PTH activity and maintaining normocalcemia with the convenience of a patient-centric once-weekly dosing regimen. Feedback from physicians and patients has reinforced strong interest in a less burdensome treatment option, which we believe should translate into enthusiastic enrollment in the Phase 3 trial, and we look forward to enrolling the first patient in Q3 2026 now that we have confirmed the regulatory path toward an NDA submission.”
Based on feedback from the FDA, MBX plans to advance once-weekly canvuparatide into a Phase 3 trial in the third quarter of 2026. Phase 3 trial design elements have now been selected, including the number of patients, primary endpoint (including proportion of participants who achieve normal serum calcium and independence from conventional therapy) and key secondary endpoints (including normalization of urinary calcium), as well as dose selection, titration schedule and duration of the study.
The Phase 3 double-blind placebo-controlled trial will enroll approximately 160 patients, randomized in a 3:1 ratio to receive canvuparatide or placebo. Following randomization, there will be a 4-week fixed dose period of 600 micrograms of canvuparatide (or placebo), followed by an 18-week dose-titration period, and a 4-week maintenance period. The primary efficacy analysis will be assessed at Week 26, followed by a transition to an open label extension to assess both long-term safety and durability of effect.
The Company also announced today that once-weekly canvuparatide has been granted orphan drug designation by the European Medicines Agency for the treatment of chronic hypoparathyroidism, supporting its continued clinical development in Europe.
About Canvuparatide
Canvuparatide is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of HP. Leveraging the company’s proprietary Precision Endocrine Peptide™ (PEP™) platform technology, canvuparatide was designed to provide convenient, once-weekly administration and a continuous, infusion-like PTH exposure with lower daily peak-to-trough ratios than observed with daily PTH dosing regimens. Canvuparatide received orphan drug designation from the U.S. Food and Drug Administration for the treatment of HP.
About Hypoparathyroidism (HP)
HP is a rare endocrine disease caused by a deficiency of parathyroid hormone (PTH) released by the parathyroid glands that results in decreased calcium levels in the blood, leading to hypocalcemia. Hypocalcemia can cause a variety of symptoms, such as muscle cramping or spasm, tingling, and neurological symptoms such as depression, confusion, and cognitive impairment. More serious complications can occur, including seizures and cardiac arrhythmia. HP can interfere with daily activities, negatively impacting the quality of life for patients. We estimate that HP affects more than 250,000 individuals in the U.S. and Europe. The current standard of care for HP does not address the underlying cause of the disease, PTH deficiency, and consists primarily of high doses of oral calcium and active vitamin D supplements.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) preparing for Phase 3 development; an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates; and imapextide (MBX 1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: MBX Biosciences’ expectations regarding the design of a Phase 3 trial; expectations regarding timing, including plans to initiate a Phase 3 clinical trial in Q3 2026; the potential for canvuparatide to be a new standard of care for HP; the potential market opportunity in HP; orphan drug designation and the intended benefits of such designation; and the unmet need for a new treatment option.
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect MBX Biosciences’ business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company’s research and development activities; MBX Biosciences’ ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; MBX Biosciences’ ability to attract, integrate and retain key personnel; risks related to the Company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining MBX Biosciences’ intellectual property protections; risks related to the competitive landscape for MBX Biosciences’ product candidates; and final audit adjustments and other developments that may arise that would cause MBX Biosciences’ expectations with respect to the estimate of cash, cash equivalents and marketable securities as of December 31, 2025 to differ, perhaps materially, from the financial results that will be reflected in MBX Biosciences’ audited consolidated financial statements for the fiscal year ended December 31, 2025; as well as other risks described in “Risk Factors,” in MBX Biosciences’ Quarterly Report on Form 10-Q for the three months ended September 30, 2025, Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC), as well as subsequent filings with the SEC. MBX Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
MBX Biosciences uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's Investor Relations website, in addition to following the Company's press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact:
George Shea
We. Communications
gshea@wecommunications.com
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ**
How does MBX Biosciences Inc. MBX plan to leverage the feedback from the FDA regarding the Phase 3 trial design to ensure successful enrollment and execution of the trial?
What specific regulatory milestones does MBX Biosciences Inc. MBX aim to achieve before submitting a New Drug Application for canvuparatide?
In what ways does MBX Biosciences Inc. MBX anticipate that canvuparatide will address the unmet needs of patients with chronic hypoparathyroidism compared to current treatments?
How does MBX Biosciences Inc. MBX intend to allocate resources to support both the ongoing Phase 3 trial of canvuparatide and other projects in its pipeline simultaneously?
**MWN-AI FAQ is based on asking OpenAI questions about MBX Biosciences Inc. (NASDAQ: MBX).
NASDAQ: MBX
MBX Trading
-4.92% G/L:
$31.05 Last:
117,460 Volume:
$33.24 Open:
